Images List Premium Download Classic

Autoimmune Disease

Autoimmune Disease-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Anti-pad2 antibody for treating and evaluating autoimmune and inflammatory diseases
October 04, 2018 - N°20180284118

A method for measuring anti-pad2 antibodies in a subject with an inflammatory or autoimmune disease, and to determine if the subject has a better prognosis for developing a more severe form of inflammation based on anti-pad2 antibody levels. Methods for the therapeutic use of anti-pad2 antibodies are also described..
Molecules with bimodal activity depleting target at low dose and increasing immunosuppression at higher dose
October 04, 2018 - N°20180282424

The present disclosure involves biologically active proteins termed stradobodies and having bimodal activity. Thus, the present disclosure provides compositions and methods providing both target cell destructive and immunosuppressive activities, useful in the treatment of diseases and conditions including autoimmune diseases, inflammatory diseases, infectious diseases, or cancers..
Bispecific constructs and their use in the treatment of various diseases
October 04, 2018 - N°20180282419

The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to il23r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.. .
Autoimmune Disease Patent Pack
Download 255+ patent application PDFs
Autoimmune Disease Patent Applications
Download 255+ Autoimmune Disease-related PDFs
For professional research & prior art discovery
inventor
  • 255+ full patent PDF documents of Autoimmune Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method of controlling administration of cancer antigen
October 04, 2018 - N°20180280433

The present invention is directed to mammalian bi-specific t cells and methods for using these bi-specific t cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific t cells that express a viral antigen t cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also ...
Methods for predicting flare and improving treatment of patients
Kypha, Inc.
September 27, 2018 - N°20180275139

In some embodiments, the present invention provides methods for predicting flare in subjects with autoimmune disease (e.g., lupus erythematosus). In some embodiments, pending flares may be reduced in severity and/or prevented from clinical manifestation in their entirety using provided methods.
Method to identify subjects at higher risk to develop an autoimmune disease based on genetic ...
University Of California, Berkeley
September 27, 2018 - N°20180274033

The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble interleukin 7 receptor (sil7r), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble interleukin-7 receptor (sil7...
Autoimmune Disease Patent Pack
Download 255+ patent application PDFs
Autoimmune Disease Patent Applications
Download 255+ Autoimmune Disease-related PDFs
For professional research & prior art discovery
inventor
  • 255+ full patent PDF documents of Autoimmune Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
Viela Bio, Inc.
September 27, 2018 - N°20180273621

The present invention provides chimeric and humanized versions of anti-cd19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human cd19 antigen and that may mediate adcc, cdc, and/or apoptosis for the treatment of b cell diseases and disorders, such as, but not limited to, b cell ...
Glycotargeting therapeutics
École Polytechnique Fédérale De Lausanne (epfl)
September 27, 2018 - N°20180271986

Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to ...
Methods related to tim 3, a th1-specific cell surface molecule, for activating antigen presenting cells
Dana-farber Cancer Institute, Inc.
September 27, 2018 - N°20180271977

The present invention provides compositions and methods useful for promoting or reducing t-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (apc) activation.
Method and device for detecting antigen-specific antibodies in a biological fluid sample by using neodymium ...
The U.s.a., As Represented By The Secretary, Department Of Health And Human Services
September 20, 2018 - N°20180267031

Methods for detecting antigen-specific antibodies in a biological sample are described. The disclosed methods can be used for the diagnosis of a variety of autoimmune and infectious diseases.
Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
Biogen Ma Inc.
September 20, 2018 - N°20180265925

The present invention relates to molecular signatures that can be used to identify patients diagnosed with an autoimmune disease, in particular with systemic lupus erythematosus for treatment with a cd40 or cd40l antagonist such as anti-cd40 antibody, anti-cd40l antibody or a binding fragment thereof. The signatures can also be used to monitor target engagement and response to treatment..
Complement split product c4d for the treatment of inflammatory conditions
Medizinische Universität Wien
September 20, 2018 - N°20180265557

The present invention relates to a pharmaceutical composition comprising complement split product c4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The c4d to be used may be a multimer.
Treatment of autoimmune diseases
Biogen Inc.
September 20, 2018 - N°20180264107

The present invention concerns treatment of autoimmune diseases with antagonists which bind to b cell surface markers, such as cd19 or cd20.. .
Autoimmune Disease Patent Pack
Download 255+ patent application PDFs
Autoimmune Disease Patent Applications
Download 255+ Autoimmune Disease-related PDFs
For professional research & prior art discovery
inventor
  • 255+ full patent PDF documents of Autoimmune Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Rna polymerase i inhibitors and uses thereof
Tel Hashomer Medical Research Infrastructure And Services Ltd.
September 20, 2018 - N°20180264002

Provided are novel compounds which are capable of inhibiting an activity of rna polymerase i, and uses thereof in treating diseases or disorders modulated by rna polymerase i, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.. .
Methods of treating conditions related to the s1p1 receptor
Arena Pharmaceuticals, Inc.
September 20, 2018 - N°20180263958

Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (s1p1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (r)-2-(7-(4-cyclopentyl-3-(trifluoro-methyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 ...
Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application ...
September 13, 2018 - N°20180258393

The invention provides methods for the ex-vivo expansion of cd4+cd25+ tregs. The invention provides a method for producing ex vivo expanded tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens.
Cell penetrating peptides that inhibit irf5 nuclear localization
September 13, 2018 - N°20180258148

The invention provides inhibitors of interferon regulatory factor 5 (irf5) nuclear localization and methods of using the inhibitors to treat autoimmune diseases such as systemic lupus erythematosus (sle).. .
Novel compounds
September 13, 2018 - N°20180258132

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous ...
Substituted amino triazoles useful as human chitinase inhibitors
September 13, 2018 - N°20180258071

Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase.
Soluble mediator
September 13, 2018 - N°20180256679

The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a ...
Treatments for autoimmune disease
September 13, 2018 - N°20180256583

The invention relates to a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis. In a further embodiment of the invention there is provided a molecule capable of acting as substrate for the queuine-insertase enzyme complex and where said molecule is not a substrate for hypoxanthine-guanine phosphoribosyltransferase and said molecule has the effect of lowering interferon gamma, for ...
Loading